Filing Flows › Enanta Pharmaceuticals (ENTA) › Q4 FY25
Enanta Pharmaceuticals (ENTA) Q4 FY25 earnings results (fourth quarter fiscal 2025)
10-K filed Nov 19, 2025
Enanta Pharmaceuticals (ENTA) reported revenue of $15.1M for the fourth quarter fiscal 2025 (Q4 FY25), +4% from a year earlier and -17% from the quarter before. Operating margin was -121.6%, net loss $18.7M (123.6% of revenue).
Enanta Pharmaceuticals, Q4 FY25: revenue $15.1M (+4% year over year), operating margin -121.6%, net loss $18.7M, operating cash flow −$6.5M. The chart follows the revenue to costs, profit and cash.
| Q4 FY25 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $15.1M | -17% | +4% |
| Operating profit | −$18.4M | — | — |
| Net earnings | −$18.7M | — | — |
| Operating cash flow | −$6.5M | -137% | — |
What changed
Revenue was $15.1M in Q4 FY25, up 4% year over year and down 17% from the previous quarter.
Operating costs exceeded revenue by $18.4M, an operating margin of -121.6%. Total costs fell 25% while revenue rose 4%. The quarter ended with a net loss of $18.7M, wider than the previous quarter's $18.3M loss.
Operating cash flow was −$6.5M. Non-cash charges added back $1.3M of depreciation and amortization and $4.0M of share-based compensation. Working capital and other items added $6.9M. Capital expenditures of $1.5M exceeded it, leaving free cash flow of −$7.9M.
Questions
What was Enanta Pharmaceuticals' revenue in the fourth quarter fiscal 2025?
Enanta Pharmaceuticals (ENTA) reported revenue of $15.1M for the fourth quarter fiscal 2025 (Q4 FY25), +4% from a year earlier and -17% from the quarter before.
Was Enanta Pharmaceuticals profitable in the fourth quarter fiscal 2025?
Operating loss was $18.4M (-121.6% of revenue) and net loss $18.7M.